Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Behind the Clinical Trials for Non-Alcohol Fatty Liver Disease that Can Benefit 30% of Americans

The Impact Research Institute (IRI) is Waco, Texas’ resource for extending care options for NAFLD (non-alcohol fatty liver disease.) Nadege Gunn is IRI’s Medical Director and President. She joined Kevin Stevenson on I Don’t Care to discuss her and her team’s mission to treat NAFLD and other related diseases and conditions. Dr. Gunn is…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from I Don't Care on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

The Impact Research Institute (IRI) is Waco, Texas’ resource for extending care options for NAFLD (non-alcohol fatty liver disease.) Nadege Gunn is IRI’s Medical Director and President. She joined Kevin Stevenson on I Don’t Care to discuss her and her team’s mission to treat NAFLD and other related diseases and conditions.

Dr. Gunn is a Gastroenterologist and Hepatologist whose main passion is the liver. “The liver is an amazing organ,” Dr. Gunn said. “It’s the only organ in the body that you could cut in half, and it can grow back in full size in about three months. The work we do in transplantation and replacing the liver is quite amazing, so that’s why I chose the field in general.”

Dr. Gunn helped open IRI in July of 2021. Necessity created the decision to develop the center. While practicing clinical trials in Austin, Texas, Dr. Gunn saw many patients traveling from the Waco area to receive treatment options for NAFLD. With no scan or clinical trial options available to people in Waco and the surrounding area, Dr. Gunn recognized an opportunity to open a clinic to serve the growing needs.

Community outreach is critical to the clinic’s role in Waco, TX. When they identify candidates who may have NAFLD, they do a non-invasive scan at the center to determine if the candidate does have the disease. “If they do, then we invite them to maybe participate in a clinical trial because there are no treatments for fatty liver,” Dr. Gunn said.

For people wondering if they might have NAFLD, Dr. Gunn said the disease is often asymptomatic in the early stages. “It is when the disease is progressing, when it is starting to injure and harm the liver, that people might start firstly feeling fatigued,” Dr. Gunn said. “They might feel pain in the right upper quadrant of their abdomen and their belly.” Recognizing these warning signs and seeking a diagnosis is critical before full-on cirrhosis of the liver occurs.

More Like This Story:

Providing Real-Time Feedback for Virtual Health

Tearing Down the Barrier of Prior Authorization Through Automation

I Don't Care

Part of this channel

I Don't Care

Candid healthcare leadership conversations with Kevin Stevenson

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Wearables, AI diagnostics, and cybersecurity converge as healthcare's operational pressure points in 2026

Wearables, AI diagnostics, and cybersecurity converge as healthcare's operational pressure points in 2026

Wearable technology, AI diagnostics, and cybersecurity are becoming critical operational areas in healthcare by 2026. Companies like Samsung and GE HealthCare are advancing in these fields with new technologies, while cybersecurity incidents like the AnMed attack highlight the vulnerabilities in health systems. Healthcare providers must prioritize innovation and security to adapt to these emerging challenges.

  • 01Samsung's FDA-cleared Galaxy Ring represents an advancement in wearable health technology.
  • 02GE HealthCare has introduced a new AI-enabled ultrasound system.
  • 03The AnMed cyberattack underscores the urgent need for robust cybersecurity measures in healthcare.

Aug 13, 2026

TSP: Yvonne Commodore-Mensah

TSP: Yvonne Commodore-Mensah

The article discusses topics within the healthcare industry, focusing on contributions and insights from professionals in the field. It may delve into innovative practices or emerging trends shaping the sector. The discussion could also include expert opinions and potential strategies for improvement.

Aug 13, 2026

AI is compressing drug discovery timelines from years to months, and clinical operators need to prepare now

AI is compressing drug discovery timelines from years to months, and clinical operators need to prepare now

Generative AI is accelerating drug discovery processes, significantly reducing timelines from years to mere months. Clinical operators must adapt to this rapid change as AI-designed solutions become integral to the healthcare pipeline.

  • 01Generative AI is capable of reducing drug discovery timelines from years to months.
  • 02The integration of AI into healthcare is necessitating changes in clinical operations.
  • 03AI-informed patients are becoming more common in clinical settings.

Aug 12, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512